Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Tolerance of EGb 761® 120mg Two Times a Day on Dementia of Alzheimer Type's Onset in Patients Suffering From Memory Complaints. A Randomised, Double-blind, Multicentre, Parallel Groups, Placebo Controlled Phase IIIb/IV Study in Elderly Over 70

NCT00276510 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT00276510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00276510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Tolerance of EGb 761® 120mg Two Times a Day on Dementia of Alzheimer Type's Onset in Patients Suffering From Memory Complaints. A Randomised, Double-blind, Multicentre, Parallel Groups, Placebo Controlled Phase IIIb/IV Study in Elderly Over 70
Lead sponsor
Ipsen
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2002
Completion date
November 30, 2009
Enrollment
2,878 (actual)
Sites
698

Conditions

As the registry lists them; a condition with its own page is linked.

memory disorders, age-related, retention disorders, cognitive